Citizens analyst Jonathan Wolleben lowered the firm’s price target on KalVista (KALV) to $28 from $29 and keeps an Outperform rating on the shares. KalVista’s Q4 results aligned with the preannouncement, with $49M in global sales for Ekterly through year-end, reflecting a strong launch in the underappreciated on-demand HAE market that appears resilient despite newer prophylactic therapies, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista price target raised to $42 from $39 at Stifel
- KalVista reports 8M EPS ($2.03) vs. ($2.30) last year
- KalVista sees cash runway through profitability
- Early Outperformance and Expanding On‑Demand HAE Opportunity Justify Buy Rating on KalVista
- KalVista announces new data from sebetralstat clinical trial program